Effect of paclitaxel in gefitinib-resistant non-small cell lung cancer (NSCLC) treatment during the COVID-19 pandemic.

被引：0
|
作者：
Mohiuddin, Md [1 ]
Kasahara, Kazuo [1 ]
机构：
[1] Kanazawa Univ, Dept Resp Med, Kanazawa, Ishikawa, Japan
来源：
CLINICAL CANCER RESEARCH | 2020年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P27
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib-Resistant Non-Small Cell Lung Cancer
    Wang, Ya
    Zhang, Guixi
    Zhou, Zhilan
    Zhang, Ning
    Jiang, Hang
    Liu, Yichang
    Fu, Ting
    Zhu, Yingdi
    Li, Juan
    ADVANCED HEALTHCARE MATERIALS, 2025, 14 (02)
  • [22] Overexpression and extended degradation rate of Axl in acquired gefitinib-resistant non-small cell lung cancer cells
    Kim, Donghwa
    Bach, Duc-Hiep
    Hong, Ji-Young
    Park, Hyen Joo
    Lee, Sang Kook
    CANCER RESEARCH, 2018, 78 (13)
  • [23] Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic
    Karaman, Elanur
    Ulas, Arife
    Onder, Arif Hakan
    Deligonul, Adem
    Orhan, Sibel O.
    Pekcolaklar, Atilla
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [24] Apoptotic effect of a single compound derived from natural product in Gefitinib-resistant non-small cell lung cancer cells
    Fan, Xing-Xing
    Wong, Maria Pik
    Cao, Zhi-Wei
    Li, Na
    Wu, Jin-Lin
    Zhou, Hua
    Jiang, Zhi-Hong
    Liu, Liang
    Leung, Elaine Lai-Han
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Carboplatin and Weekly Paclitaxel for the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) During Pregnancy
    Azim, Hatem A., Jr.
    Scarfone, Giovanna
    Peccatori, Fedro A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (04) : 559 - 560
  • [26] SYNERGISTIC INTERACTIONS OF GEFITINIB, AFATINIB, CETUXIMAB AND DASATINIB AGAINST GEFITINIB RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, Alex Y.
    Wang, Miao
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S453 - S453
  • [27] A phase II trial of weekly paclitaxel (P) and gefitinib (G) in patients (pts) with gefitinib-refractory or -resistant non-small cell lung cancer (NSCLC).
    Kasahara, K
    Sone, T
    Kimura, H
    Yoshimoto, A
    Araya, T
    Iwasa, KI
    Shirasaki, H
    Shintani, H
    Fujimura, M
    Nakao, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [28] Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
    Jeong, Chul-Ho
    Park, Hee Baek
    Jang, Won Jun
    Jung, Su Hyun
    Seo, Young Ho
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 224 - 227
  • [29] Role of adenosine A2a receptors in the growth control of a gefitinib-resistant non-small cell lung cancer cell growth
    Noguchi, Maki
    Kuzumaki, Naoko
    Nagasawa, Atsumi
    Narita, Michiko
    Narita, Minoru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 197P - 197P
  • [30] Effect of gefitinib challenge to initial treatment with non-small cell lung cancer
    Chen, Xiaofeng
    Li, Wei
    Hu, Xiaoli
    Geng, Yiting
    Wang, Rong
    Yin, Yongmei
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (08) : 542 - 546
12345